{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:41:53Z","timestamp":1762249313703,"version":"3.37.3"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.neurobiolaging.2010.04.035","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:26:53Z","timestamp":1277080013000},"page":"194.e5-194.e15","source":"Crossref","is-referenced-by-count":29,"title":["5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA"],"prefix":"10.1016","volume":"33","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieke","family":"Winkelmolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","article-title":"Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells","volume":"36","author":"Aghajanian","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","article-title":"L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study","volume":"195","author":"Arai","year":"1995","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib5","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(97)00531-3","article-title":"A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey","volume":"766","author":"Bezard","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib7","doi-asserted-by":"crossref","first-page":"15248","DOI":"10.1073\/pnas.0606578103","article-title":"Activation, internalization, and recycling of the serotonin 2A receptor by dopamine","volume":"103","author":"Bhattacharyya","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib9","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1523\/JNEUROSCI.3465-08.2008","article-title":"Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis","volume":"28","author":"Boulet","year":"2008","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1098-2396(20010315)39:4<297::AID-SYN1012>3.0.CO;2-Q","article-title":"Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum","volume":"39","author":"Bubser","year":"2001","journal-title":"Synapse"},{"issue":"suppl 3","key":"10.1016\/j.neurobiolaging.2010.04.035_bib11","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib12","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog. Brain Res"},{"issue":"suppl 3","key":"10.1016\/j.neurobiolaging.2010.04.035_bib14","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S1353-8020(08)70014-2","article-title":"L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment","volume":"13","author":"Cenci","year":"2007","journal-title":"Parkinsonism Relat. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","article-title":"Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex","volume":"861","author":"Chen","year":"1998","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0026-895X(25)13392-0","article-title":"Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles","volume":"33","author":"Darchen","year":"1988","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","article-title":"Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor","volume":"14","author":"Fahn","year":"1971","journal-title":"J. Neurol. Sci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease \u2212 opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog. Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: On movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchemneu.2007.06.004","article-title":"L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys","volume":"35","author":"Huot","year":"2008","journal-title":"J. Chem. Neuroanat"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib32","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease [in Japanese]","volume":"54","author":"Kannari","year":"2002","journal-title":"No Shinkei"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib33","first-page":"295","article-title":"Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study","volume":"75","author":"Katzenschlager","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0024-3205(81)90747-5","article-title":"Receptor binding profile of R41 four hundred and sixty-eight, a novel antagonist at five-HT2 receptors","volume":"28","author":"Leysen","year":"1981","journal-title":"Life Sci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0026-895X(25)14623-3","article-title":"[3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites","volume":"21","author":"Leysen","year":"1982","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1096-9861(20010122)429:4<571::AID-CNE5>3.0.CO;2-X","article-title":"Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H] MDL100,nine hundred and seven autoradiography and in situ hybridization studies","volume":"429","author":"Lopez-Gimenez","year":"2001","journal-title":"J. Comp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","article-title":"Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum","volume":"74","author":"Lucas","year":"2000","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.32.5.514","article-title":"The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture","volume":"32","author":"Marsden","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/nimg.1996.0036","article-title":"A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy","volume":"4","author":"Martin","year":"1996","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9861(19971208)389:1<1::AID-CNE1>3.0.CO;2-6","article-title":"Regional and cellular distribution of serotonin 5-hydroxytryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat","volume":"389","author":"Mijnster","year":"1997","journal-title":"J. Comp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0304-3940(87)90408-3","article-title":"The use of 14C-labeled tissue paste standards for the calibration of 125I-labeled ligands in quantitative autoradiography","volume":"81","author":"Miller","year":"1987","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0166-4328(96)00111-8","article-title":"Ca2+ mobilizing agents mimic serotonin five-HT2A facilitation of N-methyl-D-aspartate depolarization","volume":"73","author":"Neuman","year":"1996","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.biopsych.2005.06.037","article-title":"Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide","volume":"59","author":"Oquendo","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Brain Res. Rev"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(85)90857-1","article-title":"Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-two receptors","volume":"346","author":"Pazos","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0306-4522(87)90327-7","article-title":"Serotonin receptors in the human brain \u2212 IV","volume":"21","author":"Pazos","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-four-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0006-8993(91)91444-6","article-title":"Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset","volume":"567","author":"Perez-Otano","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib55","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0306-4522(91)90080-8","article-title":"Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey","volume":"44","author":"Pifl","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0014-2999(93)90109-U","article-title":"Activation of 5-HT2 receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate","volume":"231","author":"Rahman","year":"1993","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib57","first-page":"653","article-title":"ACP-one hundred and three, a 5-HT2A receptor inverse agonist","volume":"7","author":"Roberts","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib58","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib60","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1046\/j.1471-4159.1994.62041382.x","article-title":"Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine","volume":"62","author":"Schmidt","year":"1994","journal-title":"J. Neurochem"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib63","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-one hundred and three, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib64","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib65","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A","article-title":"Serotonin five-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex","volume":"27","author":"Willins","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0028-3908(97)00023-3","article-title":"Molecular cloning and pharmacological characterization of guinea pig 5-HT1B and 5-HT1D receptors","volume":"36","author":"Zgombick","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib68","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2010.04.035_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.physbeh.2007.05.033","article-title":"Changes on five-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model","volume":"92","author":"Zhang","year":"2007","journal-title":"Physiol. Behav"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458010002101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458010002101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T02:49:35Z","timestamp":1740192575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458010002101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0197458010002101"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.04.035","relation":{},"ISSN":["0197-4580"],"issn-type":[{"type":"print","value":"0197-4580"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}